Barclays PLC Boosts Stake in Iradimed Corporation (NASDAQ:IRMD)

Barclays PLC increased its stake in Iradimed Corporation (NASDAQ:IRMD) by 113.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,774 shares of the medical equipment provider’s stock after purchasing an additional 12,657 shares during the period. Barclays PLC owned approximately 0.19% of Iradimed worth $1,196,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Huntington National Bank grew its holdings in shares of Iradimed by 51.3% during the 3rd quarter. Huntington National Bank now owns 1,487 shares of the medical equipment provider’s stock valued at $75,000 after purchasing an additional 504 shares during the last quarter. Gladius Capital Management LP boosted its holdings in Iradimed by 126.6% during the 3rd quarter. Gladius Capital Management LP now owns 1,727 shares of the medical equipment provider’s stock valued at $87,000 after acquiring an additional 965 shares during the period. Quantbot Technologies LP grew its position in Iradimed by 83.0% during the 3rd quarter. Quantbot Technologies LP now owns 2,320 shares of the medical equipment provider’s stock worth $117,000 after acquiring an additional 1,052 shares during the last quarter. SG Americas Securities LLC purchased a new position in Iradimed in the 3rd quarter worth approximately $147,000. Finally, Principal Financial Group Inc. bought a new stake in Iradimed in the third quarter valued at approximately $246,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

Insider Activity at Iradimed

In other Iradimed news, CFO John Glenn sold 2,500 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $54.18, for a total value of $135,450.00. Following the sale, the chief financial officer now directly owns 4,383 shares of the company’s stock, valued at approximately $237,470.94. The trade was a 36.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 37.10% of the stock is currently owned by corporate insiders.

Iradimed Stock Down 0.1 %

Shares of Iradimed stock opened at $56.51 on Tuesday. The company’s fifty day simple moving average is $54.50 and its two-hundred day simple moving average is $49.80. Iradimed Corporation has a 12-month low of $40.18 and a 12-month high of $58.41. The firm has a market cap of $716.15 million, a PE ratio of 38.71 and a beta of 0.81.

Iradimed Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, November 25th. Stockholders of record on Friday, November 15th were paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 1.06%. The ex-dividend date was Friday, November 15th. Iradimed’s payout ratio is presently 41.10%.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.